

# NHL: Follicular and Marginal Zone Lymphoma Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_ Stage: \_\_\_\_\_

Line of Therapy: \_\_1<sup>st</sup> Line \_\_2<sup>nd</sup> Line \_\_3<sup>rd</sup> Line \_\_3<sup>rd</sup> Line+ \_\_Maint ECOG Performance Status: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_

Biomarkers/Characteristics: (select all that apply)

CD20 status: \_\_Negative \_\_Positive HIV associated lymphoma: \_\_No \_\_Yes Transplant Candidate: \_\_No \_\_Yes

## Gastric MALT (Mucosa-Associated Lymphoid Tissue) Lymphoma | Stage IE or IIE | *H. pylori* Positive\*

Antibiotic therapy† for *H. pylori* eradication

## Splenic Marginal Zone‡ or Gastric MALT Lymphoma | First Line of Therapy (1<sup>st</sup> Line)

Rituximab monotherapy

## Follicular (Grade I-IIIa) and Other Marginal Zone Lymphomas | First Line of Therapy (1<sup>st</sup> Line)

**BR**: Bendamustine (Bendeka, Treanda) and rituximab

**R-CHOP(21)**: Cyclophosphamide, doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, and rituximab

**R-CVP**: Cyclophosphamide, vincristine (Vincasar), prednisone, and rituximab

Rituximab monotherapy

## Follicular and Other Marginal Zone Lymphomas | First Line of Therapy (1<sup>st</sup> Line) | Additional options for the elderly or infirm

Chlorambucil (Leukeran)

Chlorambucil (Leukeran) and rituximab

Cyclophosphamide

Cyclophosphamide and rituximab

## Follicular Lymphoma (Grade III) | First Line of Therapy (1<sup>st</sup> Line)

**R-CHOP(21)**: Cyclophosphamide, doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, and rituximab

**R-CEOP**: Cyclophosphamide, etoposide, vincristine (Vincasar), prednisone, and rituximab

\* Gastric MALT with translocation 11;18 (t11;18) (q21;q21) predicts a lower response rate to anti-*H. pylori* treatment. Radiation therapy or other local intervention may be indicated.

† Only generic antibiotics are considered pathway options for *H. pylori* eradication. Clarithromycin and either amoxicillin OR metronidazole are sample regimens that may be selected to maintain pathway adherence. The actual regimen prescribed should be based on current guidelines, local antibiotic resistance patterns, and the most affordable choices.

‡ Splenectomy is also a recommended option for splenic marginal zone lymphoma (NCCN 2A)

**Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.**



8600 West Bryn Mawr Avenue  
South Tower - Suite 800 Chicago, IL 60631  
[www.aimspecialtyhealth.com](http://www.aimspecialtyhealth.com)

Last review: 4/28/2020 | Effective date: 5/4/2020

Appropriate.Safe.Affordable  
© 2020 AIM Specialty Health  
9009-0720